Mirum Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by LIVMARLI
Mirum Pharmaceuticals (MIRM) reported strong third-quarter results for 2026, with net product sales reaching $185.7 million, a 40% increase compared to the same period last year. This growth was primarily driven by its lead product, LIVMARLI, which generated $133.4 million in revenue due to steady uptake in Alagille syndrome and expansion into the adult PFIC market. Despite the top-line growth, the company reported a net loss of $40.8 million for the quarter, compared to a profit in the prior year, largely due to increased R&D and commercial expansion efforts. However, management raised its full-year 2026 revenue guidance to a range of $715 million to $720 million and highlighted the recent launch of ATEBRIOZ for FOP patients as a key upcoming catalyst.
Topics: Financial Guidance Net Loss Product Sales Revenue Growth